| 公開日期 | 標題 | 作者 | 來源出版物 | WOS | 全文 |
| 2016 | Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors | Spinner, M. A.; Vina, M. F.; Elder, L.; Arai, S.; Johnston, L.; Meyer, E.; Miklos, D.; Muffly, L.; Negrin, R. S.; Shizuru, J.; Wen-Kai Weng ; Laport, G. G.; Strober, S.; Lowsky, R.; Rezvani, A. R. | Blood | | |
| 2007 | Autologous cytokine-induced killer cells as post-transplant cellular immunotherapy | Arai, S.; Sheehan, K.; Moore, S.; Laport, G.; Johnston, L.; Lowsky, R.; Miklos, D.; Goldstein, K.; Wen-Kai Weng ; Shizuru, J.; Horning, S.; Negrin, R. | Blood | | |
| 2015 | Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms | Narayan, R.; Benjamin, J.; Laport, G.; Tian, L.; Tate, K.; Elder, L.; Galvez, L.; Armstrong, R.; Sheehan, K.; Lowsky, R.; Arai, S.; Johnston, L.; Miklos, D.; Muffly, L. S.; Rezvani, A. R.; Shizuru, J.; Wen-Kai Weng ; Strober, S.; Negrin, R.; Meyer, E. | Blood | | |
| 2009 | A Dose Escalation Trial of Imatinib for Steroid Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFRA Antibody Analysis | Chen, G. L.; Arai, S.; Flowers, M. E. D.; Otani, J.; Cheng, E. C.; McMillan, A.; Wen-Kai Weng ; Shizuru, J.; Johnston, L.; Miklos, D. | Blood | | |
| 2013 | Early Infusion Of Donor-Derived CIK Cells As Consolidative Immunotherapy Following Non-Myeloablative Allogeneic Transplantation: Safety and Feasibility | Benjamin, J.; Laport, G. G.; Tate, K.; Galvez, L.; Armstrong, R.; Sheehan, K.; Arai, S.; Lowsky, R.; Johnston, L.; Miklos, D. B.; Shizuru, J.; Wen-Kai Weng ; Negrin, R. | Blood | | |
| 2018 | Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation | Muffly, L.; Sheehan, K.; Armstrong, R.; Jensen, K.; Tate, K.; Rezvani, A. R.; Miklos, D.; Arai, S.; Shizuru, J.; Johnston, L.; Meyer, E.; Wen-Kai Weng ; Laport, G. G.; Negrin, R. S.; Strober, S.; Lowsky, R. | Blood Advances | | |
| 2016 | Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma | Neppalli, A. K.; Shizuru, J.; Johnston, L. J.; Muffly, L. S.; Wen-Kai Weng ; Negrin, R.; Meyer, E.; Laport, G.; Lowsky, R.; Arai, S.; Miklos, D. B.; Rezvani, A. R. | Journal of Clinical Oncology | | |
| 2020 | Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma | Wen-Kai Weng ; Arai, S.; Rezvani, A.; Johnston, L.; Lowsky, R.; Miklos, D.; Shizuru, J.; Muffly, L.; Meyer, E.; Negrin, R. S.; Wang, E.; Almazan, T.; Million, L.; Khodadoust, M.; Li, S. F.; Hoppe, R. T.; Kim, Y. H. | Blood Advances | | |
| 2008 | Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Non-Myeloablative Conditioning with Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Confirm a Low Incidence of Graft Versus Host Disease (GVHD) with Retained Anti-Tumor Activity | Kohrt, H.; Turnbull, B.; Laport, G.; Miklos, D.; Shizuru, J.; Johnston, L.; Arai, S.; Wen-Kai Weng ; Benjamin, J.; Blume, K.; Negrin, R.; Lavori, P.; Strober, S.; Lowsky, R. | Blood | | |
| - | Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma | Lemieux, C.; Muffly, L. S.; Rezvani, A.; Lowsky, R.; Iberri, D. J.; Craig, J. K.; Frank, M. J.; Johnston, L. J.; Liedtke, M.; Negrin, R.; Wen-Kai Weng ; Meyer, E.; Shizuru, J.; Shiraz, P.; Arai, S.; Miklos, D. B.; Sidana, S. | Bone Marrow Transplantation | | |
| 2016 | Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation | Muffly, L. S.; Sheehan, K.; Armstrong, R.; Tate, K.; Tudisco, C.; Rezvani, A. R.; Miklos, D.; Arai, S.; Shizuru, J.; Johnston, L.; Meyer, E.; Wen-Kai Weng ; Laport, G. G.; Negrin, R. S.; Strober, S.; Lowsky, R. | Blood | | |
| 2008 | Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma | Arai, S.; Letsinger, R.; Johnston, L.; Laport, G.; Lowsky, R.; Miklos, D.; Shizuru, J.; Wen-Kai Weng ; Wong, R.; Lavori, P.; Blume, K.; Negrin, R.; Horning, S. | Blood | | |
| 2008 | Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results in Low Chronic Gvhd | Arai, S.; Sahaf, B.; Jones, C.; Zhender, J.; Lowsky, R.; Strober, S.; Shizuru, J.; Negrin, R.; Johnston, L.; Laport, G.; Schaenman, J.; Brown, J.; Wen-Kai Weng ; Letsinger, R.; Wong, R.; Lavori, P.; Miklos, D. | Blood | | |
| 2019 | Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients | Meyer, E. H.; Laport, G.; Xie, B. J.; MacDonald, K.; Heydari, K.; Sahaf, B.; Tang, S. W.; Baker, J.; Armstrong, R.; Tate, K.; Tadisco, C.; Arai, S.; Johnston, L.; Lowsky, R.; Muffly, L.; Rezvani, A. R.; Shizuru, J.; Wen-Kai Weng ; Sheehan, K.; Miklos, D.; Negrin, R. S. | Jci Insight | | |
| 2016 | Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation | Veeraputhiran, M.; Arai, S.; Lowsky, R.; Miklos, D. B.; Meyer, E.; Muffly, L. S.; Negrin, R.; Rezvani, A. R.; Shizuru, J.; Wen-Kai Weng ; Johnston, L. J. | Journal of Clinical Oncology | | |
| 2017 | Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation | Veeraputhiran, M.; Yang, L. Y.; Sundaram, V.; Arai, S.; Lowsky, R.; Miklos, D.; Meyer, E.; Muffly, L.; Negrin, R.; Rezvani, A.; Shizuru, J.; Wen-Kai Weng ; Johnston, L. | Biology of Blood and Marrow Transplantation | | |
